What is claimed is:

1. A compound of Formula (I):



(I)

wherein:

Het is selected from the group consisting of:



R^1 is selected from hydrogen, alkyl, alkyl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino, cyclopropyl and halogen, cycloalkyl, cycloalkyl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino and halogen, cycloalkyl containing from 1 to 4 heteroatoms, cycloalkyl containing from 1 to 4 heteroatoms substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino and halogen, C_1-C_{12}aryl and C_1-C_{12}aryl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino and halogen;

R^4 is selected from hydrogen, halogen, alkyl, substituted alkyl, cycloalkyl, cycloalkyl containing from 1 to 4 heteroatoms and a cyclic or

polycyclic aromatic ring containing from 3 to 16 carbon atoms and optionally containing one or more heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring contains at least one heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, alkoxy, acetamide, cyano, nitrile, urea, substituted urea, aryl, substituted cycloalkyl, substituted aryl, aryloxy, oxo, hydroxy, alkoxy, cycloalkyl, acyloxy, amino, N-acylamino, nitro, halogen, $-C(O)OR^2$, $-C(O)NR^5R^6$, $-S(O)_2NR^5R^6$, $-S(O)_nR^2$ and protected -OH,
where n is 0-2,
R^2 is selected from hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and
R^5 and R^6 are independently hydrogen, cycloalkyl, C_1-C_{12}aryl, substituted cycloalkyl, substituted C_1-C_{12}aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, $-C(O)OR^2$, $-S(O)_nR^2$, $-C(O)NR^2R^3$, $-S(O)_2NR^2R^3$, nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, aryl, substituted aryl and protected –OH, or R^5 and R^6 taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen, where the ring is optionally subtituted with one or more substituents selected from amino, methylamino and dimethylamino,

where R^2 and R^3 are independently hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and n is 0-2; and

R^7 is selected from hydrogen, $-C(O)NR^9R^{10}$, $-(CH_2)_nNR^9R^{10}$, $-SO_2NR^9R^{10}$, $-(CH_2)_nOR^8$, $-O-(CH_2)_mNR^9R^{10}$ and $-N-(CH_2)_mNR^9R^{10}$,
where n is 0-2,
m is 1-6, where the carbon chain formed by m is optionally substituted,
R^8 is alkyl, cycloalkyl, cycloalkyl containing from 1 to 4 heteroatoms, and aryl, each of which is optionally substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, amino substituted with one or more substituents selected

from the group consisting of: hydroxy, alkoxy and amino, N-acylamino, oxo, hydroxy, $-C(O)OR^2$, $-S(O)_nR^2$, $-C(O)NR^2R^3$, $-S(O)_2NR^2R^3$, nitro, guanadine, substituted guanadine, cyano, cycloalkyl, cycloalkyl containing from 1 to 4 heteroatoms, substituted cycloalkyl containing from 1 to 4 heteroatoms, substituted cycloalkyl, halogen, aryl, substituted aryl and protected –OH,

where R^2 and R^3 are independently hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and n is 0-2,

R^9 and R^{10} are independently hydrogen, cycloalkyl, cycloalkyl containing from 1 to 4 heteroatoms, C_1-C_{12}aryl, substituted cycloalkyl, substituted C_1-C_{12}aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, methylamino, dimethylamino, hydroxyalkyl, $-C(O)OR^2$, $-S(O)_nR^2$, $-C(O)NR^2R^3$, $-S(O)_2NR^2R^3$, $-NR^2R^3$, nitro, cyano, cycloalkyl, cycloalkyl containing from 1 to 4 heteroatoms, substituted cycloalkyl, halogen, aryl, substituted aryl and protected –OH,

or R^9 and R^{10} taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen, where the ring is optionally subtituted with one or more substituents selected from amino, methylamino and dimethylamino,

where R^2 and R^3 are independently hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and n is 0-2;

except 4-[1-Ethyl-7-(piperidin-4-yloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-ylamine.

2. A pharmaceutically acceptable salt, hydrate, solvate or pro-drug of a compound of Formula (I), as described in claim 1.

3. A compound of Claim 1 represented by the following Formula (II):



(II)

wherein:

R^1 is selected from hydrogen, alkyl, alkyl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino, cyclopropyl and halogen, cycloalkyl, cycloalkyl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino and halogen, cycloalkyl containing from 1 to 4 heteroatoms, cycloalkyl containing from 1 to 4 heteroatoms substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino and halogen, C_1-C_{12}aryl and C_1-C_{12}aryl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino and halogen;

R^4 is selected from hydrogen, halogen, alkyl, substituted alkyl, cycloalkyl, cycloalkyl containing from 1 to 4 heteroatoms and a cyclic or polycyclic aromatic ring containing from 3 to 16 carbon atoms and optionally containing one or more heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring contains at least one heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, alkoxy, acetamide, cyano, nitrile, urea, substituted urea, aryl, substituted cycloalkyl, substituted aryl, aryloxy, oxo, hydroxy, alkoxy, cycloalkyl, acyloxy, amino, N-acylamino, nitro, halogen, $-C(O)OR^2$, $-C(O)NR^5R^6$, $-S(O)_2NR^5R^6$, $-S(O)_nR^2$ and protected -OH,
where n is 0-2,
R^2 is selected from hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and
R^5 and R^6 are independently hydrogen, cycloalkyl, C_1-C_{12}aryl, substituted cycloalkyl, substituted C_1-C_{12}aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, $-C(O)OR^2$, -

$S(O)_nR^2$, $-C(O)NR^2R^3$, $-S(O)_2NR^2R^3$, nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, aryl, substituted aryl and protected –OH, or R^5 and R^6 taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen, where the ring is optionally subtituted with one or more substituents selected from amino, methylamino and dimethylamino,

where R^2 and R^3 are independently hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and n is 0-2; and

R^7 is selected from hydrogen, $-C(O)NR^9R^{10}$, $-(CH_2)_nNR^9R^{10}$, $-SO_2NR^9R^{10}$, $-(CH_2)_nOR^8$, $-O-(CH_2)_mNR^9R^{10}$ and $-N-(CH_2)_mNR^9R^{10}$,

where n is 0-2,

m is 1-6, where the carbon chain formed by m is optionally substituted,

R^8 is alkyl, cycloalkyl, cycloalkyl containing from 1 to 4 heteroatoms, and aryl, each of which is optionally substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, amino substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy and amino, N-acylamino, oxo, hydroxy, $-C(O)OR^2$, $-S(O)_nR^2$, $-C(O)NR^2R^3$, $-S(O)_2NR^2R^3$, nitro, guanadine, substituted guanadine, cyano, cycloalkyl, cycloalkyl containing from 1 to 4 heteroatoms, substituted cycloalkyl containing from 1 to 4 heteroatoms, substituted cycloalkyl, halogen, aryl, substituted aryl and protected –OH,

where R^2 and R^3 are independently hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and n is 0-2,

R^9 and R^{10} are independently hydrogen, cycloalkyl, cycloalkyl containing from 1 to 4 heteroatoms, C_1-C_{12}aryl, substituted cycloalkyl, substituted C_1-C_{12}aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, methylamino, dimethylamino, hydroxyalkyl, $-C(O)OR^2$, $-S(O)_nR^2$, $-C(O)NR^2R^3$, $-S(O)_2NR^2R^3$, $-NR^2R^3$, nitro, cyano, cycloalkyl, cycloalkyl containing from 1 to 4

heteroatoms, substituted cycloalkyl, halogen, aryl, substituted aryl and protected –OH,

or R^9 and R^{10} taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen, where the ring is optionally subtituted with one or more substituents selected from amino, methylamino and dimethylamino,

where R^2 and R^3 are independently hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and n is 0-2;

except 4-[1-Ethyl-7-(piperidin-4-yloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-ylamine.

4. A pharmaceutically acceptable salt, hydrate, solvate or pro-drug of a compound of Formula (II), as described in claim 3.

5. A compound of Claim 1 represented by the following Formula (III):



(III)

wherein:

R^1 is selected from alkyl, alkyl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino, cyclopropyl and halogen, cycloalkyl, cycloalkyl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino and halogen, cycloalkyl containing from 1 to 3 heteroatoms, cycloalkyl containing from 1 to 3 heteroatoms substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino and halogen, C_1-C_{12}aryl and C_1-C_{12}aryl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino and halogen;

R^4 is selected from hydrogen, halogen, alkyl, substituted alkyl, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms and a cyclic or polycyclic aromatic ring containing from 3 to 16 carbon atoms and optionally containing one or more heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring contains at least one heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, alkoxy, acetamide, cyano, nitrile, urea, substituted urea, aryl, substituted cycloalkyl, substituted aryl, aryloxy, oxo, hydroxy, alkoxy, cycloalkyl, acyloxy, amino, N-acylamino, nitro, halogen, $-C(O)OR^2$, $-C(O)NR^5R^6$, $-S(O)_2NR^5R^6$, $-S(O)_nR^2$ and protected -OH, where n is 0-2,

R^2 is selected from hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and

R^5 and R^6 are independently hydrogen, cycloalkyl, C_1-C_{12}aryl, substituted cycloalkyl, substituted C_1-C_{12}aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, $-C(O)OR^2$, $-S(O)_nR^2$, $-C(O)NR^2R^3$, $-S(O)_2NR^2R^3$, nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, aryl, substituted aryl and protected –OH, or R^5 and R^6 taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen, where the ring is optionally subtituted with one or more substituents selected from amino, methylamino and dimethylamino,

where R^2 and R^3 are independently hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and n is 0-2; and

R^7 is selected from $-C(O)NR^9R^{10}$, $-(CH_2)_nNR^9R^{10}$, $-SO_2NR^9R^{10}$, $-(CH_2)_nOR^8$, $-O-(CH_2)_mNR^9R^{10}$ and $-N-(CH_2)_mNR^9R^{10}$, where n is 0-2,

m is 1-6, where the carbon chain formed by m is optionally substituted,

R^8 is alkyl, piperidine, imidazolidine, phenyl, piperazine, piperidyl and pyrrolidinyl, each of which is optionally substituted with one or more

substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, amino substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy and amino, N-acylamino, oxo, hydroxy, $-C(O)OR^2$, $-S(O)_nR^2$, $-C(O)NR^2R^3$, $-S(O)_2NR^2R^3$, nitro, guanadine, substituted guanadine, cyano, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, substituted cycloalkyl containing from 1 to 3 heteroatoms, substituted cycloalkyl, halogen, aryl, substituted aryl and protected –OH,

where R^2 and R^3 are independently hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and n is 0-2,

R^9 and R^{10} are independently hydrogen, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, C_1-C_{12}aryl, substituted cycloalkyl, substituted C_1-C_{12}aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, methylamino, dimethylamino, hydroxyalkyl, $-C(O)OR^2$, $-S(O)_nR^2$, $-C(O)NR^2R^3$, $-S(O)_2NR^2R^3$, $-NR^2R^3$, nitro, cyano, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, substituted cycloalkyl, halogen, aryl, substituted aryl and protected –OH,

or R^9 and R^{10} taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen, where the ring is optionally subtituted with one or more substituents selected from amino, methylamino and dimethylamino,

where R^2 and R^3 are independently hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and n is 0-2;

except 4-[1-Ethyl-7-(piperidin-4-yloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-ylamine.

6. A pharmaceutically acceptable salt, hydrate, solvate or pro-drug of a compound of Formula (III), as described in claim 5.

7. A compound represented by Formula (II), as defined in claim 3, wherein:

R^1 is selected from: alkyl, alkyl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino, cyclopropyl and halogen, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms and C_1-C_{12}aryl;

R^4 is selected from hydrogen, halogen, alkyl, substituted alkyl, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, C_1-C_{12}aryl and C_1-C_{12}aryl substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, alkoxy, acetamide, cyano, nitrile, urea, substituted urea, aryloxy, hydroxy, alkoxy, acyloxy, amino, N-acylamino, nitro and halogen; and

R^7 is selected from, $-C(O)NR^9R^{10}$, $-(CH_2)_nNR^9R^{10}$, $-(CH_2)_nOR^8$, $-O-(CH_2)_mNR^9R^{10}$ and $-N-(CH_2)_mNR^9R^{10}$,
where n is 0-2;
m is 1-6, where the carbon chain formed by m is optionally substituted,
R^8 is alkyl, piperidine, imidazolidine, phenyl, piperazine, piperidyl and pyrrolidinyl, each of which is optionally substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, amino substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy and amino, N-acylamino, hydroxy, nitro, guanadine, substituted guanadine, cyano, cycloalkyl, substituted cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, substituted cycloalkyl containing from 1 to 3 heteroatoms, halogen, C_1-C_{12}aryl and substituted C_1-C_{12}aryl,
R^9 and R^{10} are independently hydrogen, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, C_1-C_{12}aryl, substituted cycloalkyl, substituted C_1-C_{12}aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, methylamino, dimethylamino, hydroxyalkyl, $-NR^2R^3$, nitro, cyano, cycloalkyl, halogen, aryl and substituted aryl,
or R^9 and R^{10} taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen, where the ring is optionally subtituted with one or more substituents selected from amino, methylamino and dimethylamino,

where R^2 and R^3 are independently hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl;

except 4-[1-Ethyl-7-(piperidin-4-yloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-ylamine.

8. A pharmaceutically acceptable salt, hydrate, solvate or pro-drug of a compound of Formula (II), as described in claim 7.

9. A compound represented by Formula (III), as defined in claim 5, wherein:

R^1 is selected from: alkyl, alkyl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino, cyclopropyl and halogen, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms and C_1-C_{12}aryl;

R^4 is selected from hydrogen, halogen, alkyl, substituted alkyl, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, C_1-C_{12}aryl and C_1-C_{12}aryl substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, alkoxy, acetamide, cyano, nitrile, urea, substituted urea, aryloxy, hydroxy, alkoxy, acyloxy, amino, N-acylamino, nitro, and halogen; and

R^7 is selected from $-(CH_2)_nOR^8$, $-O-(CH_2)_mNR^9R^{10}$ and $-N-(CH_2)_mNR^9R^{10}$,
where n is 0-2;
m is 1-6, where the carbon chain formed by m is optionally substituted,
R^8 is alkyl, piperidine, imidazolidine, phenyl, piperazine, piperidyl and pyrrolidinyl, each of which is optionally substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, amino substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy and amino, N-acylamino, hydroxy, nitro, guanadine, substituted guanadine, cyano, cycloalkyl, substituted cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, substituted cycloalkyl containing from 1 to 3 heteroatoms, halogen, C_1-C_{12}aryl and substituted C_1-C_{12}aryl,

R^9 and R^{10} are independently hydrogen, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, C_1-C_{12}aryl, substituted cycloalkyl, substituted C_1-C_{12}aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, methylamino, dimethylamino, hydroxyalkyl, -NR^2R^3, nitro, cyano, cycloalkyl, halogen, aryl and substituted aryl,

or R^9 and R^{10} taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen, where the ring is optionally subtituted with one or more substituents selected from amino, methylamino and dimethylamino,

where R^2 and R^3 are independently hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl;

except 4-[1-Ethyl-7-(piperidin-4-yloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-ylamine.

10. A pharmaceutically acceptable salt, hydrate, solvate or pro-drug of a compound of Formula (II), as described in claim 9.

11. A compound represented by Formula (I), as defined in claim 1, wherein:

R^1 is selected from alkyl, alkyl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino, cyclopropyl and halogen, cycloalkyl, cycloalkyl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino and halogen, cycloalkyl containing from 1 to 3 heteroatoms, cycloalkyl containing from 1 to 3 heteroatoms substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino and halogen, C_1-C_{12}aryl and C_1-C_{12}aryl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino and halogen;

R^4 is selected from hydrogen, halogen, alkyl, substituted alkyl, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms and a cyclic or polycyclic aromatic ring containing from 3 to 16 carbon atoms and optionally containing one or more heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring contains at least one heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, alkoxy, acetamide, cyano, nitrile, urea, substituted urea, aryl, substituted cycloalkyl, substituted aryl, aryloxy, oxo, hydroxy, alkoxy, cycloalkyl, acyloxy, amino, N-acylamino, nitro, halogen, $-C(O)OR^2$, $-C(O)NR^5R^6$, $-S(O)_2NR^5R^6$ and $-S(O)_nR^2$,
where n is 0-2,
R^2 is selected from hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and
R^5 and R^6 are independently hydrogen, cycloalkyl, C_1-C_{12}aryl, substituted cycloalkyl, substituted C_1-C_{12}aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, $-C(O)OR^2$, $-S(O)_nR^2$, $-C(O)NR^2R^3$, $-S(O)_2NR^2R^3$, nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, aryl and substituted aryl,
or R^5 and R^6 taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen, where the ring is optionally subtituted with one or more substituents selected from amino, methylamino and dimethylamino,

where R^2 and R^3 are independently hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and n is 0-2; and

R^7 is selected from $-(CH_2)_nOR^8$, $-O-(CH_2)_mNR^9R^{10}$ and $-N-(CH_2)_mNR^9R^{10}$,
where n is 0-2,
m is 1-6, where the carbon chain formed by m is optionally substituted,
R^8 is alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, amino substituted with one or more substituents selected from the group consisting of:

hydroxy, alkoxy and amino, N-acylamino, oxo, hydroxy, -C(O)OR^2, -$S(O)_nR^2$, -$C(O)NR^2R^3$, -$S(O)_2NR^2R^3$, nitro, guanadine, substituted guanadine, cyano, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, substituted cycloalkyl, substituted cycloalkyl containing from 1 to 3 heteroatoms, halogen, aryl and substituted aryl, cycloalkyl and cycloalkyl containing from 1 to 3 heteroatoms, each of said cycloalkyl and cycloalkyl containing from 1 to 3 heteroatoms is optionally substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, -C(O)OR^2, -$S(O)_nR^2$, -$C(O)NR^2R^3$, -$S(O)_2NR^2R^3$, nitro, cyano, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, substituted cycloalkyl, halogen, aryl and substituted aryl,

where R^2 and R^3 are independently hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and n is 0-2,

R^9 and R^{10} are hydrogen, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, C_1-C_{12}aryl, substituted cycloalkyl, substituted C_1-C_{12}aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, methylamino, dimethylamino, hydroxyalkyl, -C(O)OR^2, -$S(O)_nR^2$, -$C(O)NR^2R^3$, -$S(O)_2NR^2R^3$, -NR^2R^3, nitro, cyano, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, substituted cycloalkyl, halogen, aryl and substituted aryl,

where R^2 and R^3 are independently hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and n is 0-2;

except 4-[1-Ethyl-7-(piperidin-4-yloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-ylamine.

12. A pharmaceutically acceptable salt, hydrate, solvate or pro-drug of a compound of Formula (I), as described in claim 11.

13. A compound represented by Formula (II), as defined in claim 3, wherein:

R^1 is selected from alkyl, alkyl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-

acylamino, cyclopropyl and halogen, cycloalkyl, cycloalkyl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino and halogen, cycloalkyl containing from 1 to 3 heteroatoms, cycloalkyl containing from 1 to 3 heteroatoms substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino and halogen, C_1-C_{12}aryl and C_1-C_{12}aryl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino and halogen;

R^4 is selected from hydrogen, halogen, alkyl, substituted alkyl, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms and a cyclic or polycyclic aromatic ring containing from 3 to 16 carbon atoms and optionally containing one or more heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring contains at least one heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, alkoxy, acetamide, cyano, nitrile, urea, substituted urea, aryl, substituted cycloalkyl, substituted aryl, aryloxy, oxo, hydroxy, alkoxy, cycloalkyl, acyloxy, amino, N-acylamino, nitro, halogen, $-C(O)OR^2$, $-C(O)NR^5R^6$, $-S(O)_2NR^5R^6$ and $-S(O)_nR^2$,
where n is 0-2,
R^2 is selected from hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and
R^5 and R^6 are independently hydrogen, cycloalkyl, C_1-C_{12}aryl, substituted cycloalkyl, substituted C_1-C_{12}aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, $-C(O)OR^2$, $-S(O)_nR^2$, $-C(O)NR^2R^3$, $-S(O)_2NR^2R^3$, nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, aryl and substituted aryl,
or R^5 and R^6 taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen, where the ring is optionally subtituted with one or more substituents selected from amino, methylamino and dimethylamino,

where R^2 and R^3 are independently hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and n is 0-2; and

R^7 is selected from $-(CH_2)_nOR^8$, $-O-(CH_2)_mNR^9R^{10}$ and $-N-(CH_2)_mNR^9R^{10}$,
where n is 0-2,
m is 1-6, where the carbon chain formed by m is optionally substituted,
R^8 is alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, amino substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy and amino, N-acylamino, oxo, hydroxy, $-C(O)OR^2$, $-S(O)_nR^2$, $-C(O)NR^2R^3$, $-S(O)_2NR^2R^3$, nitro, guanadine, substituted guanadine, cyano, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, substituted cycloalkyl, substituted cycloalkyl containing from 1 to 3 heteroatoms, halogen, aryl and substituted aryl, cycloalkyl and cycloalkyl containing from 1 to 3 heteroatoms, each of said cycloalkyl and cycloalkyl containing from 1 to 3 heteroatoms is optionally substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, $-C(O)OR^2$, $-S(O)_nR^2$, $-C(O)NR^2R^3$, $-S(O)_2NR^2R^3$, nitro, cyano, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, substituted cycloalkyl, halogen, aryl and substituted aryl,
where R^2 and R^3 are independently hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and n is 0-2,
R^9 and R^{10} are hydrogen, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, C_1-C_{12}aryl, substituted cycloalkyl, substituted C_1-C_{12}aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, methylamino, dimethylamino, hydroxyalkyl, $-C(O)OR^2$, $-S(O)_nR^2$, $-C(O)NR^2R^3$, $-S(O)_2NR^2R^3$, $-NR^2R^3$, nitro, cyano, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, substituted cycloalkyl, halogen, aryl and substituted aryl,
where R^2 and R^3 are independently hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and n is 0-2;

except 4-[1-Ethyl-7-(piperidin-4-yloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-ylamine.

14. A pharmaceutically acceptable salt, hydrate, solvate or prodrug of a compound of Formula (II), as described in claim 13.

15. A compound represented by Formula (I), as defined in claim 1, wherein:

R^1 is selected from alkyl, alkyl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino, cyclopropyl and halogen, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms and C_1-C_{12}aryl;

R^4 is selected from hydrogen, halogen, alkyl, substituted alkyl, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, C_1-C_{12}aryl and C_1-C_{12}aryl substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, alkoxy, acetamide, cyano, nitrile, urea, substituted urea, aryloxy, hydroxy, alkoxy, acyloxy, amino, N-acylamino, nitro and halogen; and

R^7 is selected from $-(CH_2)_nOR^8$, $-O-(CH_2)_mNR^8R^9$ and $-N-(CH_2)_mNR^8R^9$,
where n is 0-2,
m is 1-6, where the carbon chain formed by m is optionally substituted,
R^8 is alkyl substituted with one or more substituents selected from the group consisting of: cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, substituted cycloalkyl, substituted cycloalkyl containing from 1 to 3 heteroatoms, aryl and substituted aryl,
R^9 is hydrogen, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, C_1-C_{12}aryl, substituted cycloalkyl, substituted C_1-C_{12}aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, methylamino, dimethylamino, hydroxyalkyl, $-C(O)OR^2$, $-S(O)_nR^2$, $-C(O)NR^2R^3$, $-S(O)_2NR^2R^3$, $-NR^2R^3$, nitro, cyano, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, substituted cycloalkyl, halogen, aryl and substituted aryl,

where R^2 and R^3 are independently hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and n is 0-2.

16. A pharmaceutically acceptable salt, hydrate, solvate or pro-drug of a compound of Formula (I), as described in claim 15.

17. A compound represented by Formula (II), as defined in claim 3, wherein:

R^1 is selected from alkyl, alkyl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino, cyclopropyl and halogen, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms and C_1-C_{12}aryl;

R^4 is selected from hydrogen, halogen, alkyl, substituted alkyl, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, C_1-C_{12}aryl and C_1-C_{12}aryl substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, alkoxy, acetamide, cyano, nitrile, urea, substituted urea, aryloxy, hydroxy, alkoxy, acyloxy, amino, N-acylamino, nitro and halogen; and

R^7 is selected from $-(CH_2)_nOR^8$, $-O-(CH_2)_mNR^8R^9$ and $-N-(CH_2)_mNR^8R^9$,
where n is 0-2,
m is 1-6, where the carbon chain formed by m is optionally substituted,
R^8 is alkyl substituted with one or more substituents selected from the group consisting of: cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, substituted cycloalkyl, substituted cycloalkyl containing from 1 to 3 heteroatoms, aryl and substituted aryl,
R^9 is hydrogen, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, C_1-C_{12}aryl, substituted cycloalkyl, substituted C_1-C_{12}aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, methylamino, dimethylamino, hydroxyalkyl, $-C(O)OR^2$, $-S(O)_nR^2$, $-C(O)NR^2R^3$, $-S(O)_2NR^2R^3$, $-NR^2R^3$, nitro, cyano,

cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, substituted cycloalkyl, halogen, aryl and substituted aryl,

where R^2 and R^3 are independently hydrogen, alkyl, cycloalkyl, C_1-C_{12}aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12}aryl, and n is 0-2.

18. A pharmaceutically acceptable salt, hydrate, solvate or pro-drug of a compound of Formula (II), as described in claim 17.

19. A compound represented by Formula (I), as defined in claim 1, wherein:

R^1 is selected from alkyl, alkyl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino, cyclopropyl and halogen, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms and C_1-C_{12}aryl;

R^4 is selected from hydrogen, halogen, alkyl, substituted alkyl, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, C_1-C_{12}aryl and C_1-C_{12}aryl substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, alkoxy, acetamide, cyano, nitrile, urea, substituted urea, aryloxy, hydroxy, alkoxy, acyloxy, amino, N-acylamino, nitro and halogen; and

R^7 is selected from $-(CH_2)_nOR^8$, $-O-(CH_2)_mNR^8R^9$ and $-N-(CH_2)_mNR^8R^9$,
where n is 0-2,
m is 1-6 , where the carbon chain formed by m is optionally substituted,
R^8 is alkyl substituted with one or more substituents selected from the group consisting of: piperidine, substituted piperidine, phenyl and, substituted phenyl,
R^9 is hydrogen, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, C_1-C_{12}aryl, substituted cycloalkyl, substituted C_1-C_{12}aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, methylamino, dimethylamino, hydroxyalkyl, nitro,

cyano, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, halogen and aryl.

20. A pharmaceutically acceptable salt, hydrate, solvate or prodrug of a compound of Formula (I), as described in claim 19.

21. A compound represented by Formula (II), as defined in claim 3, wherein:

R^1 is selected from alkyl, alkyl substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, amino, N-acylamino, cyclopropyl and halogen, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms and C_1-C_{12}aryl;

R^4 is selected from hydrogen, halogen, alkyl, substituted alkyl, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, C_1-C_{12}aryl and C_1-C_{12}aryl substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, alkoxy, acetamide, cyano, nitrile, urea, substituted urea, aryloxy, hydroxy, alkoxy, acyloxy, amino, N-acylamino, nitro and halogen; and

R^7 is selected from $-(CH_2)_nOR^8$, $-O-(CH_2)_mNR^8R^9$ and $-N-(CH_2)_mNR^8R^9$,
where n is 0-2,
m is 1-6 , where the carbon chain formed by m is optionally substituted,
R^8 is alkyl substituted with one or more substituents selected from the group consisting of: piperidine, substituted piperidine, phenyl and, substituted phenyl,
R^9 is hydrogen, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, C_1-C_{12}aryl, substituted cycloalkyl, substituted C_1-C_{12}aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, methylamino, dimethylamino, hydroxyalkyl, nitro, cyano, cycloalkyl, cycloalkyl containing from 1 to 3 heteroatoms, halogen and aryl.

22. A pharmaceutically acceptable salt, hydrate, solvate or pro-drug of a compound of Formula (II), as described in claim 21.

23. A compound of claim 1 selected from:

4-(4-Phenyl-1-piperidin-4-yl-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-ylamine;

4-[4-(3-Chloro-phenyl)-1-piperidin-4-yl-1H-imidazo-[4,5-c]pyridin-2-yl]furazan-3-ylamine;

4-[1-(3-Amino-2,2-dimethylpropyl)-4-(3-chlorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-ylamine;

4-[1-(cyclopropylmethyl)-4-(2-methylphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[4-(2-chlorophenyl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[1-(3-Amino-2,2-dimethylpropyl)-4-phenyl-1H-imidazo[4,5-c]pyridinyl-2-yl]-furazan-3-ylamine;

4-[4-(3-chlorophenyl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[4-chloro-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[1-(cyclopropylmethyl)-4-(3-furanyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[1-(5-aminopentyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[1-(6-aminohexyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[1-(5-aminopentyl)-4-(3-chlorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[1-(6-aminohexyl)-4-(3-chlorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[1-(3-Amino-2,2-dimethylpropyl)-4-(3-methoxyphenyl)-1H-imidazo[4,5-c]pyridinyl-2-yl]-furazan-3-ylamine;

4-[1-(5-aminopentyl)-4-(3-thienyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[1-(6-aminohexyl)-4-(3-thienyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[4-phenyl-1-(3-piperidinylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[4-(3-chlorophenyl)-1-(3-piperidinylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[4-(4-chlorophenyl)-1-(3-piperidinylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[1-(3-aminopropyl)-4-(2-thienyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[1-(3-aminopropyl)-4-(1-piperidinyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

1-[2-(4-Aminofurazan-3-yl)-1-ethyl-4-phenyl-1-H-imidazo[4,5-c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone;

1-[2-(4-Aminofurazan-3-yl)-1-ethyl-4-thiophen-3-yl-1-H-imidazo[4,5-c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone;

1-[2-(4-Aminofurazan-3-yl)-1-ethyl-4-pyridin-yl-1-H-imidazo[4,5-c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone;

1-[2-(4-Aminofurazan-3-yl)-1-ethyl-4-pyridin-3-yl-1-H-imidazo[4,5-c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone;

1-[2-(4-Aminofurazan-3-yl)-1-ethyl-4-furan-3-yl-1-H-imidazo[4,5-c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone;

1-[2-(4-Amino-furazan-3-yl)-4-chloro-1-ethyl-1-H-imidazo[4,5-c]pyridin-7-yl]-1-(3-amino-pyrrolidin-1-yl)-methanone;

1-[2-(4-Amino-furazan-3-yl)-4-(1H-pyrrol-2-yl))-1-ethyl-1-H-imidazo[4,5-c]pyridin-7-yl]-1-(3-amino-pyrrolidin-1-yl)-methanone;

1-[2-(4-Amino-furazan-3-yl)-1-ethyl-4-(2-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-7-yl]-1-(3-amino-pyrrolidin-1-yl)-methanone;

1-[2-(4-Amino-furazan-3-yl)-1-ethyl-4-(3-chloro-phenyl)-1H-imidazo[4,5-c]pyridin-7-yl]-1-(3-amino-pyrrolidin-1-yl)-methanone;

1-[2-(4-Amino-furazan-3-yl)-1-ethyl-4-furan-2-yl-1H-imidazo[4,5-c]pyridin-7-yl]-1-(3-amino-pyrrolidin-1-yl)-methanone;

2-(4-Amino-furazan-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid [1-(4-chloro-benzyl)-2-hydroxy-ethyl]-amide;

2-(4-Amino-furazan-3-yl)-1-ethyl-4-(3-chloro-phenyl)-1H-imidazo[4,5-c]pyridine-7-carboxylic acid [1-(4-chloro-benzyl)-2-hydroxy-ethyl]-amide;

2-(4-Amino-furazan-3-yl)-1-ethyl-4-(2,3-dichloro-phenyl)-1H-imidazo[4,5-c]pyridine-7-carboxylic acid [1-(4-chloro-benzyl)-2-hydroxy-ethyl]-amide;

2-(4-Amino-furazan-3-yl)-1-ethyl-4-(2-chloro-phenyl)-1H-imidazo[4,5-c]pyridine-7-carboxylic acid [1-(4-chloro-benzyl)-2-hydroxy-ethyl]-amide;

2-(4-Amino-furazan-3-yl)-1-ethyl-4-(2-hydroxy-phenyl)-1H-imidazo[4,5-c]pyridine-7-carboxylic acid [1-(4-chloro-benzyl)-2-hydroxy-ethyl]-amide;

2-(4-Amino-furazan-3-yl)-4-(3-chloro-phenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid pyrrolidin-3-ylamide;

2-(4-Amino-furazan-3-yl)-4-phenyl-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid pyrrolidin-3-ylamide;

2-(4-Amino-furazan-3-yl)-4-(5-chloro-thiophen-2-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid pyrrolidin-3-ylamide;

2-(4-Amino-furazan-3-yl)-4-(2-amino-phenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid pyrrolidin-3-ylamide;

2-(4-Amino-furazan-3-yl)-4-(3-amino-phenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid pyrrolidin-3-ylamide;

2-(4-Amino-furazan-3-yl)-4-(3-bromo-phenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid pyrrolidin-3-ylamide;

2-(4-Amino-furazan-3-yl)-4-(1-naphthalenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid pyrrolidin-3-ylamide;

2-(4-Amino-furazan-3-yl)-4-(thiophen-2-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid pyrrolidin-3-ylamide;

2-(4-Amino-furazan-3-yl)-4-(3,4-methylenedioxyphenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid pyrrolidin-3-ylamide;

2-(4-Amino-furazan-3-yl)-4-(3,5-dichloro-phenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid pyrrolidin-3-ylamide;

4-[7-[(3-amino-1-pyrrolidinyl)carbonyl]-4-(3-chlorophenyl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[7-[(3-amino-1-pyrrolidinyl)carbonyl]-4-(4-biphenylyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[7-[(3-amino-1-pyrrolidinyl)carbonyl]-4-(2,4-dichlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-4-(phenylethynyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

2-{2-(4-amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl}phenol;

4-[7-[(3-amino-1-pyrrolidinyl)carbonyl]-4-(2-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

(2-{2-(4-amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl}phenyl)methanol;

2-{2-(4-amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl}-4-chlorophenol;

4-(1-ethyl-7-{[3-(methylamino)-1-pyrrolidinyl]carbonyl}-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-[7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-4-(4-methylphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[7-[(3-amino-1-pyrrolidinyl)carbonyl]-4-(2,5-dichlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[7-[(3-amino-1-pyrrolidinyl)carbonyl]-4-(1-benzothien-2-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[1-ethyl-4-phenyl-7-(4-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-{7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-4-[4-(methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine;

4-{2-(4-amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl}phenol;

4-[7-[(3-amino-1-pyrrolidinyl)carbonyl]-4-(4-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[4-(3-chlorophenyl)-1-ethyl-7-(4-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-(cyclopropylmethyl)-N-{2-[(phenylmethyl)amino]ethyl}-1H-imidazo[4,5-c]pyridine-7-carboxamide;

3-{2-(4-amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl}phenol;

4-{2-(4-amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl}benzonitrile;

1-[2-(4-Amino-furazan-3-yl)-4-phenyl-1-piperidin-4yl-1-H-imidazo[4,5-c]pyridin-7-yl]-1-(3-amino-pyrrolidin-1-yl)-methanone;

4-(4-(3-chlorophenyl)-1-ethyl-7-{[3-(methylamino)-1-pyrrolidinyl]carbonyl}-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-(4-(2,5-dichlorophenyl)-1-ethyl-7-{[3-(methylamino)-1-pyrrolidinyl]carbonyl}-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-[4-(2,5-dichlorophenyl)-1-ethyl-7-(4-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-(cyclopropylmethyl)-N-[3-(dimethylamino)propyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide;

4-[7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-4-(1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[7-[(3-amino-1-pyrrolidinyl)carbonyl]-4-(4-bromophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[7-[(3-amino-1-pyrrolidinyl)carbonyl]-4-phenyl-1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-{7-[(4-aminobutyl)oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine;

4-{1-ethyl-4-phenyl-7-[(4-piperidinylmethyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine;

4-{4-(3-chlorophenyl)-1-ethyl-7-[(4-piperidinylmethyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine;

4-[7-[(4-aminobutyl)oxy]-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-{7-[(2-aminoethyl)oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine;

4-{1-ethyl-4-phenyl-7-[(3-pyrrolidinylmethyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine;

4-{7-[(3-aminopropyl)oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine;

4-(7-{[(2S)-2-amino-3-phenylpropyl]oxy}-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-[1-ethyl-4-phenyl-7-(3-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-methyl-N-(1-methyl-4-piperidinyl)-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide;

N-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl}-N,1-dimethyl-4-piperidinamine;

4-(1-ethyl-4-phenyl-7-{[2-(4-piperidinyl)ethyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-{1-(4-aminobutyl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine;

4-(7-{[(2R)-2-amino-3-phenylpropyl]oxy}-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-{1-(4-aminobutyl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine;

4-(1-(4-aminobutyl)-7-{[3-(methylamino)-1-pyrrolidinyl]carbonyl}-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-{1-ethyl-7-[(4-methyl-1-piperazinyl)methyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine;

4-(1-ethyl-7-{[3-(methylamino)-1-pyrrolidinyl]methyl}-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

(3-amino-2,2-dimethylpropyl){[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl}amine;

4-(7-{[3-(dimethylamino)-1-pyrrolidinyl]methyl}-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-(1-ethyl-7-{[2-(methylamino)ethyl]oxy}-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-[1-ethyl-4-phenyl-7-({2-[(phenylmethyl)amino]ethyl}oxy)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-{1-ethyl-4-phenyl-7-[(3-piperidinylmethyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine;

4-{7-[(5-aminopentyl)oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine;

4-(7-{[3-(dimethylamino)-2,2-dimethylpropyl]oxy}-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

1-(4-aminobutyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl-N-{2-[(phenylmethyl)amino]ethyl}-1H-imidazo[4,5-c]pyridine-7-carboxamide;

2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1-methylethyl)-4-phenyl-N-3-pyrrolidinyl-1H-imidazo[4,5-c]pyridine-7-carboxamide;

4-[7-{[3-(methylamino)-1-pyrrolidinyl]carbonyl}-1-(1-methylethyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-(7-{[(3S)-3-amino-1-pyrrolidinyl]methyl}-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-[1-ethyl-7-(hexahydro-1H-1,4-diazepin-1-ylmethyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[1-ethyl-4-phenyl-7-(1-piperazinylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-(7-{[2-(dimethylamino)ethyl]oxy}-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-(1-ethyl-4-phenyl-7-{[(2S)-2-pyrrolidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-(1-ethyl-4-phenyl-7-{[(2R)-2-pyrrolidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

2-(4-amino-1,2,5-oxadiazol-3-yl)-N-(3-aminopropyl)-1-(1-methylethyl)-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide;

2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1-methylethyl)-4-phenyl-N-2-propen-1-yl-1H-imidazo[4,5-c]pyridine-7-carboxamide;

2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(4-morpholinyl)propyl]-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide;

2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[2-(1H-imidazol-4-yl)ethyl]-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide;

2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(4-methyl-1-piperazinyl)propyl]-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide;

4-[7-[(3-aminopropyl)oxy]-4-(2-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[7-[(3-aminopropyl)oxy]-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-[7-[(3-aminopropyl)oxy]-4-(4-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-{7-[(3-aminopropyl)oxy]-4-[5-chloro-2-(methyloxy)phenyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine;

N-(1-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl}-3-pyrrolidinyl)-N-methylacetamide;

2-(4-amino-1,2,5-oxadiazol-3-yl)-N-[3-(dimethylamino)propyl]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide;

2-{2-(4-amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl}-4-chlorophenol;

4-[7-[(3-aminopropyl)oxy]-1-ethyl-4-(2-pyridinyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-(7-{[3-(dimethylamino)propyl]oxy}-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-(1-ethyl-7-{[3-(4-morpholinyl)propyl]oxy}-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

2-(4-amino-1,2,5-oxadiazol-3-yl)-1-cyclopentyl-4-phenyl-N-3-pyrrolidinyl-1H-imidazo[4,5-c]pyridine-7-carboxamide;

4-{7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-cyclopentyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine;

4-(1-cyclopentyl-7-{[3-(methylamino)-1-pyrrolidinyl]carbonyl}-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-(1-ethyl-7-{[3-(methylamino)propyl]oxy}-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-{1-ethyl-7-[(3-hydrazinopropyl)oxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine;

2-[(3-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy}propyl)amino]ethanol;

4-(1-ethyl-7-{[3-(hydroxyamino)propyl]oxy}-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

(3R)-1-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl}-3-pyrrolidinol;

2-(4-amino-1,2,5-oxadiazol-3-yl)-N-[3-(diethylamino)propyl]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide;

2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(2-methyl-1-piperidinyl)propyl]-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide;

4-(1-methyl-7-{[3-(methylamino)-1-pyrrolidinyl]carbonyl}-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-{7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-methyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine;

4-(1-butyl-7-{[3-(methylamino)-1-pyrrolidinyl]carbonyl}-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-{7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-butyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine;

4-[7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-(4-fluorophenyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

N-(2-aminoethyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-fluorophenyl)-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide;

4-{1-(4-aminophenyl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine;

1-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy}-3-(4-morpholinyl)-2-propanol;

N-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]-4-piperidinecarboxamide;

4-[7-{[3-(dimethylamino)-1-pyrrolidinyl]carbonyl}-4-phenyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-(1-ethyl-7-{[2-(4-morpholinyl)ethyl]oxy}-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-(1-ethyl-4-phenyl-7-{[3-(1-piperidinyl)propyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine trifluoroacetate;

2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide;

1-(1-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl}-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one;

1-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl}-3-piperidinecarboxamide;

(2-aminoethyl)(2-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy}ethyl)amine;

4-(1-ethyl-4-phenyl-7-{[2-(1-piperazinyl)ethyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-(7-{[2-(4-acetyl-1-piperazinyl)ethyl]oxy}-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine trifluoroacetate;

4-(1-ethyl-7-{[3-(4-methyl-1-piperazinyl)propyl]oxy}-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-(1-ethyl-4-phenyl-7-{[3-(1-piperazinyl)propyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

4-(1-ethyl-4-phenyl-7-{[2-(1-piperidinyl)ethyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine trifluoroacetate;

(3-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy}propyl)[2-(dimethylamino)ethyl]methylamine;

3-[(3-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy}propyl)amino]-1,2-propanediol;

N-(3-amino-2-hydroxypropyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide;

N-(2-amino-3-hydroxypropyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide;

N-(3-{2-(4-amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl}phenyl)-N'-phenylurea;

3-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy}-1-propanol;

(4-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl}-2-piperazinyl)methanol;

4-[1-ethyl-7-({3-[(methyloxy)methyl]-1-piperazinyl}carbonyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine;

4-(7-{[3-({[2,4-bis(methyloxy)phenyl]methyl}amino)propyl]oxy}-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

(2S)-2-[(3-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy}propyl)amino]-4-methyl-1-pentanol;

diethyl 1-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-hydroxy-4-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]-1,2-hydrazinedicarboxylate; and

4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[3-({2-[4-(methyloxy)phenyl]ethyl}amino)propyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol.

24. A pharmaceutically acceptable salt, hydrate, solvate or pro-drug of a compound of claim 23.

25. A pharmaceutical composition comprising a compound according to claim 1, and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof and a pharmaceutically acceptable carrier.

26. A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and an effective amount of a compound of Formula (I) as described in claim 1 and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof, which process comprises bringing the compound of Formula (I) and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof into association with a pharmaceutically acceptable carrier or diluent.

27. A method of treating or lessening the severity of a disease or condition selected from cancer and arthritis in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of a

compound of Formula I, as described in claim 1 and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof.

28. The method of claim 27 wherein the mammal is a human.

29. A method of treating or lessening the severity of a disease or condition selected from cancer and arthritis in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of a compound of Formula II, as described in claim 3 and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof.

30. The method of claim 29 wherein the mammal is a human.

31. The method according to claim 27 wherein said cancer is selected from brain (gliomas), glioblastomas, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast, colon, head and neck, kidney, lung, liver, melanoma, ovarian, pancreatic, prostate, sarcoma and thyroid.

32. The method according to claim 29 wherein said cancer is selected from brain (gliomas), glioblastomas, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast, colon, head and neck, kidney, lung, liver, melanoma, ovarian, pancreatic, prostate, sarcoma and thyroid.

33. Use of a compound of Formula (I), as described in claim 1 and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof, in the manufacture of a medicament for use in treating or lessening the severity of a disease or condition selected from cancer and arthritis.

34. The method of inhibiting Akt activity in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of a compound of Formula I, as described in claim 1 and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof.

35. The method of claim 34 wherein the mammal is a human.

36. A method of treating cancer in a mammal in need thereof, which comprises: administering to such mammal a therapeutically effective amount of

a) a compound of Formula (I), as described in claim 1 and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof; and

b) at least one anti-neoplastic agent.

37. The method claim 36, wherein the at least one anti-neoplastic agent is selected from the group consisting essentially of anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors; non-receptor tyrosine kinase angiogenesis inhibitors; immunotherapeutic agents; proapoptotic agents; and cell cycle signaling inhibitors.

38. The method of claim 36, wherein the at least one anti-neoplastic agent is an anti-microtubule agent selected from diterpenoids and vinca alkaloids.

39. The method of claim 36, wherein the at least one anti-neoplastic agent is a diterpenoid.

40. The method of claim 36, wherein the at least one anti-neoplastic agent is a vinca alkaloid.

41. The method of claim 36, wherein the at least one anti-neoplastic agent is a platinum coordination complex.

42. The method of claim 36, wherein the at least one anti-neoplastic agent is paclitaxel, carboplatin, or vinorelbine.

43 The method of claim 36, wherein the at least one anti-neoplastic agent is paclitaxel.

44. The method of claim 36, wherein the at least one anti-neoplastic agent is carboplatin.

45. The method of claim 36, wherein the at least one anti-neoplastic agent is vinorelbine.

46. The method of claim 36, wherein the at least one anti-neoplatic agent is a signal transduction pathway inhibitor.

47. The method of claim 46, wherein the signal transduction pathway inhibitor is an inhibitor of a growth factor receptor kinase selected from the group consisting of VEGFR2, TIE2, PDGFR, BTK, IGFR-1, TrkA, TrkB, TrkC, and c-fms.

48. The method of claim 46, wherein the signal transduction pathway inhibitor is an inhibitor of a serine/threonine kinase selected from the group consisting of rafk, akt, and PKC-zeta.

49. The method of claim 46, wherein the signal transduction pathway inhibitor is an inhibitor of a serine/threonine kinase selected from the src family of kinases.

50. The method of claim 49, wherein the signal transduction pathway inhibitor is an inhibitor of c-src.

51. The method of claim 46, wherein the signal transduction pathway inhibitor is an inhibitor of Ras oncogene selected from inhibitors of farnesyl transferase and geranylgeranyl transferase.

52. The method of claim 46, wherein the signal transduction pathway inhibitor is an inhibitor of a serine/threonine kinase selected from the group consisting of PI3K.

53. The method of claim 36, wherein the at least one anti-neoplastic agent is a cell cycle signaling inhibitor.

54. The method of claim 53, wherein the cell cycle signaling inhibitor is selected from inhibitors of the group CDK2, CDK4, and CDK6.

55. A pharmaceutical combination as claimed in claim 36 for use in therapy.

56. The use of a pharmaceutical combination as claimed in claim 36 for the preparation of a medicament useful in the treatment of cancer.

57. A compound selected from:

4-(7-Bromo-4-chloro-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-1,2,5-oxadiazol-3-amine;

2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-methyl-4-phenyl-1*H*-imidazo[4,5-*c*]pyridine-7-carboxylic acid; and

Ethyl 4-chloro-5-nitro-6-phenyl-3-pyridinecarboxylate.

58. A process for preparing a compound of Formula (I), and/or pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof, which comprises converting ethyl 4-chloro-5-nitro-6-phenyl-3-pyridinecarboxylate into a compound of Formula (I), and thereafter optionally preparing a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof.

59. A process for preparing a compound of Formula (II), and/or pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof, which comprises converting 4-(7-Bromo-4-chloro-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-1,2,5-oxadiazol-3-amine into a compound of Formula (II), and thereafter optionally preparing a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof.

60. A process for preparing a compound of Formula (II), and/or pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof, which comprises converting 2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-methyl-4-phenyl-1*H*-imidazo[4,5-*c*]pyridine-7-carboxylic acid into a compound of Formula (II), and thereafter optionally preparing a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof.

61. A method of treating or lessening the severity of a disease or condition selected from cancer and arthritis in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of 4-[1-Ethyl-7-(piperidin-4-yloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-ylamine and/or a pharmaceutically acceptable salt, hydrate, solvate or pro-drug thereof.